Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Avolynt Inc
Profile last edited on: 5/26/2023      CAGE: 88H70      UEI: NHWYTVNNQNE3

Business Identifier: Mid-stage biopharma company, developing SGLT2 inhibitor drug for nonalcoholic steatohepatitis (NASH) and type 2 diabetes
Year Founded
2015
First Award
2021
Latest Award
2021
Program Status
Active
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

3200 East Highway 54 Suite 100
Raleigh, NC 27709
   (919) 659-5677
   info@avolynt.com
   www.avolynt.com
Location: Single
Congr. District: 04
County: Wake

Public Profile

Structured around developing therapeutics for rare and metabolic disease, Avolynt is a clinical stage drug development company whose lead programs target Type 2 diabetes, NASH and Post Bariatric Hypoglycemia. Developing a novel SGLT2 inhibitor for the treatment of NASH and type 2 diabetes, both programs are currently in phase 2b development.

Extent of SBIR involvement

User Avatar
Phase I Awards
1
Phase II Awards
0
Conversion Rate
0.00%
Phase I Dollars
$226,375
Phase II Dollars
$0
Total Awarded
$226,375

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2021 1 NIH $226,375
Project Title: Remogliflozin Etabonate Effect on Primary Biliary Cholangitis

Key People / Management

  James Green -- CEO

  Bentley Cheatham -- Vice President

  Steven Delmar -- CFO

  William O Wilkison

Company News

There are no news available.